<DOC>
	<DOCNO>NCT00696865</DOCNO>
	<brief_summary>This multiple ascend dose study evaluate safety tolerability repeat ascend dos AZD2624</brief_summary>
	<brief_title>AZD2624 Multiple Ascending Dose Study Japan</brief_title>
	<detailed_description />
	<criteria>Healthy young male Japanese volunteer Significant illness , judge investigator , within 2 week screen visit Day 1 Enrollment another concurrent investigational study intake investigational drug within 4 month prior screen visit Day 1 Blood loss excess 200 mL within 30 day screen visit Day 1 , excess 400 mL within 90 day screen visit Day 1 , excess 1200 mL within 1 year screen visit Day 1 Clinically relevant abnormality physical examination , vital sign , clinical chemistry , hematology urinalysis judge investigator screen pre first dose</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Phase I</keyword>
</DOC>